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Eﬃ  cacy of nitric oxide, with or without continuing 
antihypertensive treatment, for management of high blood 
pressure in acute stroke (ENOS): a partial-factorial 
randomised controlled trial
The ENOS Trial Investigators*
Summary
Background High blood pressure is associated with poor outcome after stroke. Whether blood pressure should be 
lowered early after stroke, and whether to continue or temporarily withdraw existing antihypertensive drugs, is not 
known. We assessed outcomes after stroke in patients given drugs to lower their blood pressure. 
Methods In our multicentre, partial-factorial trial, we randomly assigned patients admitted to hospital with an acute 
ischaemic or haemorrhagic stroke and raised systolic blood pressure (systolic 140–220 mm Hg) to 7 days of 
transdermal glyceryl trinitrate (5 mg per day), started within 48 h of stroke onset, or to no glyceryl trinitrate (control 
group). A subset of patients who were taking antihypertensive drugs before their stroke were also randomly assigned 
to continue or stop taking these drugs. The primary outcome was function, assessed with the modiﬁ ed Rankin Scale 
at 90 days by observers masked to treatment assignment. This study is registered, number ISRCTN99414122.
Findings Between July 20, 2001, and Oct 14, 2013, we enrolled 4011 patients. Mean blood pressure was 
167 (SD 19) mm Hg/90 (13) mm Hg at baseline (median 26 h [16–37] after stroke onset), and was signiﬁ cantly 
reduced on day 1 in 2000 patients allocated to glyceryl trinitrate compared with 2011 controls (diﬀ erence 
–7·0 [95% CI –8·5 to –5·6] mm Hg/–3·5 [–4·4 to –2·6] mm Hg; both p<0·0001), and on day 7 in 1053 patients 
allocated to continue antihypertensive drugs compared with 1044 patients randomised to stop them (diﬀ erence 
–9·5 [95% CI –11·8 to –7·2] mm Hg/–5·0 [–6·4 to –3·7] mm Hg; both p<0·0001). Functional outcome at day 90 did 
not diﬀ er in either treatment comparison—the adjusted common odds ratio (OR) for worse outcome with glyceryl 
trinitrate versus no glyceryl trinitrate was 1·01 (95% CI 0·91–1·13; p=0·83), and with continue versus stop 
antihypertensive drugs OR was 1·05 (0·90–1·22; p=0·55).
Interpretation In patients with acute stroke and high blood pressure, transdermal glyceryl trinitrate lowered blood 
pressure and had acceptable safety but did not improve functional outcome. We show no evidence to support 
continuing prestroke antihypertensive drugs in patients in the ﬁ rst few days after acute stroke.
Funding UK Medical Research Council.
Copyright © Bath et al. Open Access article distributed under the terms of CC BY.
Introduction
High blood pressure is present in 70% or more of 
patients with acute ischaemic stroke1 or haemorrhagic 
stroke. Aﬀ ected patients have a worse outcome, whether 
judged as early recurrence, death within a few weeks, or 
combined death and dependency after several months.1–4 
Lowering of blood pressure acutely after stroke might 
therefore reduce these events and improve functional 
outcome, providing that cerebral perfusion is not 
reduced in the presence of dysfunctional cerebral 
autoregulation. Several large trials have tested the 
safety and eﬃ  cacy of individual drugs or management 
strategies that lower blood pressure, with investigators 
reporting results for functional outcomes ranging 
from near-negative (SCAST)5 to neutral (IMAGES,6 
CATIS),7 to near-positive (INTERACT-2).8 With use 
of meta-regression, a U-shaped relation was shown 
between outcome and diﬀ erence in blood pressure 
between treatment groups in previous trials, with both 
large reductions or any increase in blood pressure 
associated with a worse functional outcome.9
Nitric oxide donors are candidate treatments for acute 
stroke because of several eﬀ ects—nitric oxide is a 
cerebral and systemic vasodilator that lowers blood 
pressure, modulates vascular and neuronal function, is 
neuroprotective, and inhibits apoptosis.10 In preclinical 
studies of cerebral ischaemia, nitric oxide donors reduced 
infarct lesion size and improved regional cerebral blood 
ﬂ ow and functional outcome.11 Five small clinical studies 
of nitric oxide donors have been done:12–16 intravenous 
sodium nitroprusside reduced blood pressure without 
changing cerebral blood ﬂ ow and had antiplatelet 
eﬀ ects,12 thereby precluding its use in haemorrhagic 
stroke. In four pilot trials,13–16 transdermal glyceryl 
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trinitrate lowered blood pressure, had no negative eﬀ ects 
on platelet function, did not change middle cerebral 
artery blood ﬂ ow velocity or regional cerebral blood ﬂ ow, 
improved aortic compliance, and could be given to 
patients with dysphagia. No safety concerns were present 
in these studies, and in one small single-centre trial, 
functional outcome was improved with glyceryl trinitrate 
when given within 4 h of stroke onset.16
Treatment of hypertension eﬀ ectively prevents ﬁ rst and 
recurrent stroke.17,18 As a result, many patients are taking 
blood pressure-lowering drugs at the time of any 
subsequent stroke. A common clinical problem is whether 
these drugs should be continued or stopped temporarily 
during the acute phase after stroke; the answer remains 
unclear,19 guidelines mostly ignore the question, and 
clinical practice varies.20 The multicentre Continue or 
Stop Post-Stroke Antihypertensives Collaborative Study 
(COSSACS)21 examined this question and reported, in 
763 patients, that continuing antihypertensive drugs, as 
compared with stopping them, did not change death or 
dependency at either 2 weeks or 6 months.
Continuing antihypertensive drugs might help to 
reduce early recurrence and haematoma expansion, and 
improve functional outcome after stroke, much as 
long-term blood pressure reduction reduces recurrence;18 
by preventing rebound increases in blood pressure and 
heart rate (when β blockers are stopped), which might 
induce stroke recurrence and myocardial infarction, 
respectively; and by ensuring that antihypertensive drugs 
are continued beyond hospital discharge. Alternatively, 
stopping treatment temporarily might be advantageous 
for several reasons. First, some antihypertensive drugs 
might be hazardous when started in acute stroke, as 
reported in trials of angiotensin-receptor antagonists, 
β blockers, and calcium-channel blockers.22–24 Second, 
many patients do not take their blood pressure drugs 
regularly, and so correct administration of these drugs in 
hospital can lead to large and potentially harmful falls in 
blood pressure.25 Third, antihypertensive drugs can cause 
substantial hypotension in the presence of hypovolaemia 
and dehydration, which are commonly present in 
patients with acute stroke who might not be taking ﬂ uids 
appro priately. Fourth, stopping of treatment might 
increase perfusion through collateral vessels and 
optimise salvage of penumbral tissue. Fifth, blood 
pressure-lowering drugs might worsen cerebral 
perfusion in the presence of severe ipsilateral carotid 
artery stenosis. Sixth, drugs taken orally could lead to 
aspiration and pneumonia in the presence of dysphagia. 
Finally, oral administration of drugs might not be 
possible if the patient has dysphagia and enteral access 
has not yet been done; furthermore, those antihyper-
tensive drugs that are embedded in a slow-release or 
modiﬁ ed-release mechanism are not suitable to be 
taken via nasogastric tubes. As a result, continuation of 
treatment immediately after admission might not be 
possible in many patients after stroke.
We report the ﬁ ndings of the Eﬃ  cacy of Nitric Oxide in 
Stroke (ENOS) partial-factorial randomised controlled 
trial. We aimed to assess the safety and eﬃ  cacy of glyceryl 
trinitrate given within 48 h to patients with acute ischaemic 
or haemorrhagic stroke and high blood pressure. We also 
aimed to assess outcomes for a subset of patients who 
continued or stopped taking antihypertensive drugs for 
1 week after their stroke.
Methods
Participants
Between July 20, 2001, and Oct 14, 2013, we did an 
international multicentre randomised, placebo-controlled, 
patient-masked, outcome-assessor-masked, parallel-group 
trial. The full ENOS protocol is available online. Details of 
the design and statistical analysis plan have been 
published26,27 and are summarised in the appendix. In 
brief, patients were randomly assigned to 7 days of 
treatment with transdermal glyceryl trinitrate (also known 
as nitroglycerin, nitroglycerine, or trinitroglycerin) or no 
glyceryl trinitrate. In addition, a subset of patients who 
were taking blood pressure-lowering drugs immediately 
before their stroke were randomly assigned to continue or 
stop these drugs temporarily in a partial-factorial design.26
Patients were eligible for the trial if they were admitted 
to hospital with a clinical stroke syndrome due to 
ischaemic or haemorrhagic stroke, were aged 18 years or 
older, had a motor deﬁ cit in their arm or leg or both, had 
a systolic blood pressure of 140–220 mm Hg, and could 
be treated within 48 h of onset.26 The diagnosis of 
ischaemic or haemorrhagic stroke was conﬁ rmed with 
CT or MRI done before or by 7 days after enrolment with 
standard imaging techniques. Key exclusion criteria 
included a deﬁ nite need to start (eg, for thrombolysis), 
continue, or stop blood pressure-lowering drugs; need 
for, or contrain dication to, glyceryl trinitrate; coma 
(Glasgow coma scale score <8); pure sensory stroke; 
isolated dysphasia; preceding moderate or severe 
dependency (modiﬁ ed Rankin scale [mRS] score 3–5); 
confoun ding neurological or psychiatric disease; a 
disorder mimicking stroke (eg, hypoglycaemia, Todd’s 
paresis); liver dysfunction (international normalised 
ratio >1·5, amino transferase more than three-times 
normal concen trations) or renal dysfunction (creatinine 
more than three-times normal concentrations); severe 
concomitant medical disorder; pregnancy or breast-
feeding; previous participation in ENOS; planned 
surgical intervention; or participation in another trial 
within 2 weeks.
The study was approved by national and local ethics 
committees and competent authorities in each 
participating country and site, and was adopted by the 
Australian, Canadian, and UK National Institute for 
Health Research Stroke Research Networks. The trial was 
overseen by a trial steering committee (which included 
three independent members) and an international 
advisory committee (which comprised each national 
For the full ENOS protocol see 
http://www.nottingham.ac.
uk/~nszwww/enos/
enosprotocolv15.pdf
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coordinator). The day-to-day conduct of the trial was run 
by a trial management committee that was based at the 
coordinating centre in Nottingham, UK. An independent 
data monitoring committee reviewed unmasked data 
every 6 months. We obtained written informed consent 
from each patient, or from a relative or independent 
physician when the patient did not have capacity, before 
enrolment and in accordance with national regulations.
Randomisation
Investigators entered baseline and follow-up data into a 
database via a secure web-based randomisation system. 
The data were checked to conﬁ rm the patient’s eligibility 
in real time, and the computer system assigned 
participants, with one to one allocation, to glyceryl 
trinitrate or no glyceryl trinitrate, and, when relevant, to 
continue or stop prestroke antihypertensive drugs 
temporarily, each for 7 days. Treatment assign ment was 
stratiﬁ ed on the basis of country, stroke type (ischaemic 
vs haemorrhagic), and immediate prestroke use of 
antihypertensive treatment; and minimisation on key 
prognostic baseline variables: age (≤70 years vs >70 years), 
sex (female vs male), history of hypertension (no vs yes), 
history of previous stroke (no vs yes), diabetes (no vs yes), 
use of nitrate therapy immediately before stroke (no vs 
yes), stroke severity (Scandinavian stroke scale [SSS] 
>30 vs ≤30), total anterior circulation syndrome (no vs 
yes),28 systolic blood pressure (≤160 mm Hg vs 
>160 mm Hg), treatment with recombinant tissue 
plasminogen activator (yes vs no), feeding status (other vs 
intravenous ﬂ uids or nothing), and time to treatment 
(≥24 h vs <24 h); minimisation included a random 
element in 5% of patients. We used stratiﬁ cation and 
minimisation to ensure that the groups were balanced 
for prognostic factors, and the random element reduced 
predictability. The randomisation algorithm then 
presented a treatment allocation as either glyceryl 
trinitrate or no glyceryl trinitrate, and, when relevant, 
continue or stop prestroke antihypertensive drugs. Drugs 
were prescribed via the site’s hospital system. In patients 
with dysphagia, drugs were given via a nasogastric tube 
once this had been inserted.
Procedures
Treatment was started immediately after randomisation, 
was given daily for 7 days, and consisted of a glyceryl 
trinitrate dermal patch (5 mg) or no patch. Glyceryl 
trinitrate patches were sourced locally from any licensed 
manufacturer, and included the following brands: 
Deponit-5 (UCB Pharma, Brussels, Belgium; 38% of 
sites), Transiderm-Nitro (Novartis, Basel, Switzerland; 
28%), NitroDur (MSD/Schering-Plough, Kenilworth, 
NJ, USA; 25%), and Minitran (Meda/3M Healthcare, 
St Paul, MN, USA; 10%). Chinese sites obtained 
patches from a local manufacturer (Wuhan Jianmin 
Pharmaceutical Group, Wuhan, China). Patients were 
masked to glyceryl trinitrate by placing a gauze dressing 
over the patch or over a similar area of skin if they were 
assigned to no glyceryl trinitrate. The gauze dressing, 
with or without glyceryl trinitrate patch, was changed 
every day (0700–0900 h) with rotation of the site of 
placement on the shoulders or back. The dose of glyceryl 
trinitrate was not adjusted during treatment, and 
patches were left on for 24 h, such that there was 
no overnight glyceryl-trinitrate-free period. In patients 
randomly assigned to continue antihypertensive drugs, 
the same drugs and doses were started at the next 
normal time when due, and were given for 7 days. When 
appropriate, drugs were given via a nasogastric tube.
Study drugs were stopped when the patient withdrew 
consent, for safety reasons, or when unacceptable 
adverse events developed. Non-trial nitrates and other 
antihypertensive drugs were not given during the 7-day 
treatment period unless the local investigator deemed 
them necessary. Treatments under investigation were 
For more on the randomisation 
system see https://www.
nottingham.ac.uk/~nszwww/
enos/enostrialdb/enos_login.php
ENOS Continue vs stop 
antihypertensive drugs
Glyceryl 
trinitrate
No glyceryl 
trinitrate
Continue Stop
Patient characteristics
Number of patients 2000 2011 1053 1044
Age (years)* 70 (12) 70 (12) 73 (11) 73 (11)
Men* 1147 (57%) 1150 (57%) 528 (50%) 540 (52%)
Pre-morbid mRS >0 490 (25%) 536 (27%) 365 (35%) 319 (31%)
Time to random treatment assignment
Medan time (h)* 26 (16–36) 26 (16–37) 26 (16–35) 26 (15–37)
Earlier than 6 h 144 (7%) 129 (6%) 68 (6%) 75 (7%)
Geographical region‡
Asia 276 (14%) 283 (14%) 102 (10%) 100 (10%)
UK 1272 (64%) 1273 (63%) 678 (64%) 674 (65%)
Rest of Europe 322 (16%) 325 (16%) 204 (19%) 203 (19%)
Other 130 (7%) 130 (7%) 69 (7%) 67 (6%)
Medical history
Hypertension 1287 (64%) 1320 (66%) 1001 (95%) 993 (95%)
Taking antihypertensive drugs† 1057 (53%) 1081 (54%) 1047 (99%) 1039 (99%)
Stroke 315 (16%) 279 (14%) 212 (20%) 204 (20%)
Transient ischaemic attack 275 (14%) 269 (13%) 181 (17%) 171 (16%)
Ischaemic heart disease 340 (17%) 329 (16%) 255 (24%) 268 (26%)
Peripheral arterial disease 51 (3%) 66 (3%) 37 (4%) 40 (4%)
Diabetes 343 (17%) 356 (18%) 240 (23%) 244 (23%)
Hyperlipidaemia§ 552 (28%) 546 (27%) 395 (38%) 413 (40%)
Current smoker (n=3846, 96%) 459 (24%) 486 (25%) 185 (19%) 178 (18%)
Alcohol >21 units per week 140 (7%) 154 (8%) 57 (5%) 47 (5%)
Atrial ﬁ brillation, current or 
previous
395 (20%) 367 (18%) 308 (29%) 258 (25%)
Nitrate use before stroke 87 (4%) 67 (3%) 70 (7%) 66 (6%)
Haemodynamics
Systolic blood pressure (mm Hg)* 167 (19) 167 (19) 166 (19) 168 (19)
Diastolic blood pressure (mm Hg) 90 (13) 89 (13) 88 (13) 89 (13)
Mean heart rate (bpm; n=4007, 
99·9%)
78 (15) 77 (15) 77 (15) 77 (15)
(Table 1 continues on next page)
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given in addition to standard care; thrombolysis was 
permitted in patients with ischaemic stroke according to 
local practice guidelines at the recruiting site. Systematic 
use of antihypertensive drugs (all patients, after 7 days), 
and oral antithrombotic and lipid-lowering drugs (in 
patients with ischaemic stroke) were recommended for 
secondary prevention.
The ENOS website was used to record demographic 
and clinical characteristics. Investigators assessed the 
severity of the stroke with the SSS (range from 0 to 58, 
with lowest scores showing the most severe neurological 
deﬁ cit)29 at baseline and at 7 days after stroke (or at the 
time of discharge, if earlier). Blood pressure was 
measured three times using a validated automated 
monitor (OMRON Healthcare Company, Kyoto, Japan) 
supplied to each site; at least one of the three systolic 
measurements had to be in the range 140–220 mm Hg 
before enrolment. The ﬁ nal diagnosis was conﬁ rmed at 
discharge. Sites were asked to provide a trained member 
of their research staﬀ  who was unaware of treatment 
assignment to do the post-randomisation assessments in 
the hospitals. Independent expert assessors who were 
masked to treatment assignment centrally assessed CT 
and MRI scans. Independent expert adjudicators who 
were masked to treatment assignment validated and 
categorised investigator-reported serious adverse events, 
including cause-speciﬁ c deaths. We followed-up in full 
patients who did not receive their assigned treatment or 
who did not adhere to the protocol. The coordinating 
centre of each country (masked to treatment allocation) 
did the ﬁ nal follow-up centrally at 90 days by telephone. 
When the patient could not be contacted, a questionnaire 
covering the same outcome measures was sent by post.
Outcomes
The primary outcome measure was functional outcome, 
which we assessed with the mRS at 90 days after 
enrolment.30 Scores on the mRS range from 0 to 6, with a 
score of zero indicating no symptoms, ﬁ ve indicating 
severe dependency, and six denoting death. mRS is largely 
determined by motor performance, hence the need for the 
presence of motor symptoms and signs at enrolment. 
Prespeciﬁ ed secondary outcomes at day 90 included 
activities of daily living (Barthel index);31 cognition 
(modiﬁ ed telephone mini-mental state examination32 and 
telephone interview for cognition scale33); health-related 
quality of life (European quality of life-5 dimensions, 
EQ-5D,34 from which health utility status was calculated 
[EQ-5D-HUS]); and mood (short Zung depression 
score35).36 At discharge from initial admittance to hospital, 
investigators recorded duration of stay, and discharge 
destination (to institution or home).
The safety outcomes26 were all-cause case fatality and 
cause-speciﬁ c case fatality; early neurological deterioration 
(deﬁ ned as a decrease from baseline to day 7 of at least 
5 points on the SSS or decrease in consciousness of more 
than two points on the SSS consciousness domain or 
both);37 recurrent stroke by day 7; episodes of hypotension 
needing clinical intervention (such as giving intravenous 
ﬂ uids) by day 7; episodes of hypertension needing clinical 
intervention (such as administration of a treatment to 
lower blood pressure) by day 7; and serious adverse events.
Statistical analyses
The original protocol speciﬁ ed analysis of the mRS as a 
binary variable, with poor outcome deﬁ ned as an mRS of 
higher than 2 at the end of follow-up.26 On this basis, we 
determined the study sample size for the overall trial 
(glyceryl trinitrate vs no glyceryl trinitrate), and planned to 
enrol 5000 patients based on a dichotomous analysis. 
However, during the course of the trial, ordinal approaches 
to the analysis of the mRS were shown by several research 
groups to be more eﬃ  cient statistically.38,39 Therefore, the 
statistical analysis plan,27 which was submitted for 
publication before the start of data analysis and without 
knowledge of the data, speciﬁ ed that the primary analysis 
ENOS Continue vs stop 
antihypertensive drugs
Glyceryl 
trinitrate
No glyceryl 
trinitrate
Continue Stop
(Continued from previous page)
Qualifying event*‡
Ischaemic stroke 1664 (83%) 1678 (83%) 928 (88%) 904 (87%)
Intracerebral haemorrhage 310 (16%) 319 (16%) 119 (11%) 127 (12%)
Stroke, type unknown 0 1 (<1%) 0 1 (<1%)
Non-stroke 26 (1%) 13 (1%) 6 (1%) 12 (1%)
Side of lesion, right (n=4003, 
99·8%)
1023 (51%) 1063 (53%) 554 (53%) 520 (50%)
SSS score (out of 58)*¶ 34 (13) 34 (13) 32 (14) 33 (13)
NIHSS (out of 42), estimated 11 (6) 11 (6) 12 (6) 11 (6)
GCS <15|| 607 (30%) 622 (31%) 364 (35%) 363 (35%)
OCSP classiﬁ cation
Total anterior* 615 (31%) 594 (30%) 361 (34%) 336 (32%)
Partial anterior 616 (31%) 635 (32%) 349 (33%) 353 (34%)
Lacunar 695 (35%) 702 (35%) 301 (29%) 323 (31%)
Posterior 74 (4%) 80 (4%) 42 (4%) 32 (3%)
Ischaemic causative mechanisms**
Cardioembolic 365 (22%) 352 (21%) 277 (30%) 230 (25%)
Large vessel 359 (22%) 383 (23%) 197 (21%) 220 (24%)
Small vessel 639 (38%) 637 (38%) 305 (33%) 321 (36%)
Other 342 (21%) 320 (19%) 170 (18%) 160 (18%)
Not determined 34 (2%) 44 (2%) 23 (2%) 14 (1%)
Other treatment
Thrombolytic treatment* 204 (10%) 221 (11%) 123 (12%) 125 (12%)
Data are n (%), median (IQR), or mean (SD). Percentages exclude missing values from denominators. mRS=modiﬁ ed 
Rankin Scale. bpm=beats per min. SSS=Scandinavian Stroke Scale. NIHSS=National Institutes of Health Stroke Scale. 
GCS=Glasgow Coma Scale score. OCSP=Oxfordshire Community Stroke Project classiﬁ cation. *Minimisation variable. 
†Stratiﬁ cation variable. ‡Qualifying event was determined from investigator information and blinded adjudication of 
brain neuroimaging. § Hyperlipidaemia deﬁ ned locally. ¶Scores on the SSS range from 0 (coma with quadriplegia) to 
58 (normal neurological status). ||Scores on the Glasgow Coma Scale range from 3 (deep coma) to 15 (fully conscious). 
**Sum might be higher than 100% because of mixed causes.
Table 1: Baseline characteristics
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of the mRS should be done across all seven levels of the 
mRS with use of an ordinal statistical approach. As a result, 
the overall sample size was reduced by the trial steering 
committee to 3500 patients to detect a shift in the mRS 
with odds ratio (OR) 0·83 assuming an overall type 1 error 
rate of 5% with two-sided signiﬁ cance test, power 90%, 
adjustment for baseline covariates, and a drop-out rate of 
3%.27 From the beginning, we assumed that about 50% of 
patients would be taking blood pressure-lowering drugs 
before their stroke and thus go into the comparison of 
continuation versus stopping of these drugs. A total sample 
size of 1750 patients would allow a shift in mRS with an OR 
of 0·80 (or 1·25) to be detected with 80% power.
We assessed the eﬀ ect of the treatments on the primary 
outcome as a shift in mRS score,39 and adjusted for 
the factors used in minimisation at the time of 
randomisation.40 Eﬀ ects are reported as a common OR 
with 95% CI. We calculated OR and signiﬁ cance with 
ordinal logistic regression after checking that the 
assumption of proportional odds were not violated. For 
sensitivity purposes, the primary analyses were also 
analysed as unadjusted values and as a binary outcome 
(death or dependency, mRS >2, the original primary 
outcome). We assessed the heterogeneity of the treatment 
eﬀ ects on the primary outcome in prespeciﬁ ed subgroups 
by adding an interaction term to an unadjusted ordinal 
logistic regression model. We analysed mortality using 
Kaplan-Meier and Cox regression models. Because 
outcomes such as mRS, EQ-5D-HUS, and Barthel index 
include death as part of their scale (scores of 6 on mRS, 
0 on EQ-5D-HUS, and –5 on the Barthel index), and in 
case treatment was associated with asymmetric eﬀ ects 
on death and other outcome measures (eg, more death 
and less impairment), an extreme value for death was 
Figure 1: Study proﬁ le
Data are n (%). ENOS=eﬃ  cacy of nitric oxide in stroke. BP=blood pressure. GTN=glyceryl trinitrate.
4011 patients recruited
1914 (48%) not on BP-lowering drugs 2097 (52%) on BP-lowering drugs
2000 assigned GTN patch
2000 competed baseline form (100%)
1990 underwent brain scan (99%)
2011 assigned to no GTN patch
2011 competed baseline form (100%)
1999 underwent brain scan (99%)
1053 assigned to continue BP-lowering 
 drugs
1053 competed baseline form (100%)
1050 underwent brain scan (99%)
1044 assigned to stop BP-lowering drugs
1044 competed baseline form (100%)
1038 underwent brain scan (99%)
1939 (97%) received GTN on the ﬁrst day
1711 (86%) received GTN on the ﬁrst 4 days
1970 (99%) received GTN on any day
1490 (75%) received GTN on all 7 days
1999 (99%) received no GTN on the ﬁrst day
1958 (97%) received no GTN on the ﬁrst  
 4 days
2002 (99%) received no GTN on any day
1933 (96%) received no GTN on all 7 days
 745 (71%) continued drugs on the ﬁrst day
 681 (65%) continued drugs on the ﬁrst 
 4 days
1045 (99%) continued drugs on any day
 610 (58%) continued drugs on all 7 days
 987 (95%) stopped drugs on the ﬁrst day
 867 (83%) stopped drugs on the ﬁrst 
 4 days
1037 (99%) stopped drugs on any day
 810 (78%) stopped drugs on all 7 days
1664 (83%) had an ischaemic stroke
 310 (16%) had a haemorrhagic stroke
 0 had an unknown stroke type
 26 (1%) did not have a stroke
1678 (83%) had an ischaemic stroke
 319 (16%) had a haemorrhagic stroke
 1 (<1%) had an unknown stroke type
 13 (1%) did not have a stroke
928 (88%) had an ischaemic stroke
 119 (11%) had a haemorrhagic stroke
 0 had an unknown stroke type
 6 (1%) did not have a stroke
904 (87%) had an ischaemic stroke
 127 (12%) had a haemorrhagic stroke
 1 (<1%) had an unknown stroke type
 12 (1%) did not have a stroke
Day 90
 233 (12%) died
 1761 (88%) were alive
1993 (99%) had primary outcome analysis
 6 (<1%) were lost to follow-up or had no 
 vital status
Day 90
 263 (13%) died
1739 (87%) were alive
2002 (99%) had primary outcome analysis
 9 (<1%) were lost to follow-up or had no
 vital status
Day 90
 167 (16%) died
 883 (88%) were alive
1050 (99%) had primary outcome analysis
 3 (<1%) were lost to follow-up or had no 
 vital status
Day 90
 146 (14%) died
 895 (86%) were alive
1040 (99%) had primary outcome analysis
 3 (<1%) were lost to follow-up or had
 no vital status
Day 7
 61 (3%) died by day 7
1996 (99%) completed assessment 
 4 (<1%) had no information
Day 7
 58 (3%) died by day 7
2006 (99%) completed assessment 
 5 (<1%) had no information
Day 7
 34 (3%) died by day 7
1051 (99%) completed assessment 
 2 (<1%) had no information
Day 7
 27 (3%) died by day 7
1044 (100%) completed assessment 
 0 had no information
Hospital
 159 (8%) died in hospital
1988 (99%) completed assessment
 12 (1%) had no information
Hospital
 161 (8%) died in hospital
1999 (99%) completed assessment
 12 (1%) had no information
Hospital
 103 (10%) died in hospital
1045 (99%) completed assessment
 8 (1%) had no information
Hospital
 94 (9%) died in hospital
1041 (99%) completed assessment
 3 (<1%) had no information
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added to the other outcome scales: –1 for EQ-VAS, –1 for 
the modiﬁ ed telephone mini-mental state examination, 
–1 for SSS, –1 for the telephone interview for cognition 
scale, and 102·5 on the Zung self-rating depression 
scale.41 The nominal level of signiﬁ cance for all analyses 
was p<0·05 with no interim analysis. No adjustments 
were made for multiplicity of testing. We did analyses 
with SAS version 9.3 according to the intention-to-treat 
principle. This study is registered, ISRCTN99414122.
Role of the funding source
The trial was funded by grants from the UK Medical 
Research Council (G0501797), Eﬃ  cacy and Mechanism 
Evaluation (12/62/87), and BUPA foundation, and was 
sponsored by the University of Nottingham. There was 
no commercial support for the trial, and antihypertensive 
drugs were sourced locally at each site. The grant 
applicants conceived and designed the trial and wrote the 
protocol, available on the ENOS website. Study data 
were collected, monitored, and analysed by the ENOS 
Coordinating Centre. Analysis, interpretation, and report 
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all the data in the study; additionally, the corresponding 
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Results
Between July 20, 2001, and Oct 14, 2013, we enrolled 
4011 patients at 173 sites in 23 countries across 
ﬁ ve continents; of these patients, 3182 (79%) were 
enrolled in 2008 or later. 2000 patients were assigned to 
the glyceryl trinitrate group and 2011 patients were 
assigned to the no glyceryl trinitrate group (table 1). 
2097 (52%) patients were taking antihypertensive drugs 
before their stroke and were included in the continue 
(n=1053) or stop (n=1044) antihypertensive drugs groups 
of the trial. The trial was allowed to run to end of funding 
within its ethics approval, rather than stopping at the 
3500 patients required by the sample size calculation.27 
Most patients were recruited from the UK (table 1). 
3995 (>99%) patients had both vital status and the primary 
outcome recorded at day 90 (ﬁ gure 1) and one patient had 
vital status but no functional outcome.
The treatment groups were well balanced at baseline 
(table 1). Mean SSS score was 33·7 (13·2; equivalent to a 
National Institutes of Health Stroke Scale score of 
11·2 [5·7]).42 Patients who were randomised into the 
continue versus stop analysis had a more severe 
phenotype than had those who were not taking 
antihypertensive drugs before their stroke—they were 
older, more likely to be women, had higher rates of 
vascular risk factors, and were less likely to have a normal 
premorbid Rankin Scale score (table 1). Appendix p 14 
lists types and numbers of antihypertensive drugs taken 
before stroke and baseline feeding status.
Adherence with glyceryl trinitrate patches or control 
was good. 3938 (98%) patients received their ﬁ rst 
treatment as assigned, and 3669 (92%) patients had at 
least the ﬁ rst 4 days of assigned treatment—a period 
regarded (a priori) as full treatment (appendix p 15). No 
diﬀ erences were noted in the use of secondary vascular 
prophylaxis at day 7 between the two groups (data not 
shown); overall antiplatelet therapy was used in 
3033 (76%) patients, anticoagulation in 160 (4%), blood 
pressure-lowering drugs in 1493 (37%), and lipid-lowering 
drugs in 2432 (61%).
After randomisation, 745 (71%) of the patients assigned 
to continue their pre-stroke blood pressure-lowering 
drugs received their ﬁ rst treatment (ﬁ gure 1). 306 patients 
did not receive their ﬁ rst drug dose, of whom 182 (60%) 
did not have oral or enteral access, and two did not have 
data recorded at day 7. By contrast, 987 (95%) patients 
assigned to stop their treatment correctly took no tablets 
on day 1. Similar diﬀ erences between the continue and 
stop groups occurred in the ﬁ rst 4 days and for all 7 days. 
The types of blood pressure-lowering drugs taken after 
assignment were largely consistent with those taken at 
baseline in patients randomised to continue drugs 
(appendix p 16). At day 7, patients in the two groups were 
taking similar amounts of drugs for secondary vascular 
prevention—79% of patients were taking antiplatelet 
drugs, 5% taking anticoagulation drugs, and 62% taking 
lipid-lowering drugs (data not shown).
Overall mean blood pressure at baseline was 167 (SD 
19)/90 (13) mm Hg at baseline and reduced in both glyceryl 
trinitrate and no glyceryl trinitrate groups in the 7 days of 
treatment (appendix p 20). After the ﬁ rst dose, systolic and 
diastolic blood pressure were lower in the glyceryl trinitrate 
Figure 2: Distribution of modiﬁ ed Rankin Scale scores at 90 days
OR=odds ratio. 
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group by 7·0 (95% CI 5·6–8·5) mm Hg/3·5 (2·6–4·4) 
mm Hg (two-sided p<0·0001/p<0·0001) than in those 
given no glyceryl trinitrate. The diﬀ erence in blood 
pressure between the glyceryl trinitrate and no glyceryl 
trinitrate groups then diminished and did not diﬀ er 
statistically after day 3. Heart rate was 1·7 beats per min 
higher in the glyceryl trinitrate group than in the no 
glyceryl trinitrate group 1–2 h after the ﬁ rst treatment 
(p=0·045), but not at any later timepoint (data not shown).
For the continue versus stop comparison, blood 
pressure fell from baseline (167/88 mm Hg) over 1 week 
of randomised intervention in both treatment groups, 
but fell faster in those who continued their blood 
pressure-lowering drugs (appendix p 22). Mean systolic 
and diastolic blood pressure levels diﬀ ered between the 
treatment groups from day 2 after randomisation; by the 
end of the treatment phase, patients who continued their 
drugs had a blood pressure that was lower by 
9·5 (95% CI 7·2–11·8) mm Hg/5·0 (3·7–6·4) mm Hg 
(p<0·0001/p<0·0001). When considering blood pressure 
changes by the number of drugs taken before stroke 
onset, blood pressure started highest and fell most over 
7 days in individuals who continued treatment on more 
drugs (appendix p 17). In patients on a β blocker before 
their stroke, the diﬀ erence in heart rate between continue 
and stop increased over the 7 days to 8·5 beats per min 
higher in the stop group than the continue group. When 
assessing blood pressure and heart rate across 
the six treatment groups (taking account of the 
partial-factorial design), systolic and diastolic blood 
pressure and heart rate changed most in individuals 
given glyceryl trinitrate at day 1 and those who continued 
prestroke antihypertensive drugs at day 7 (appendix p 18).
When adjusted for stratiﬁ cation and minimisation 
variables, the distribution of mRS between the glyceryl 
trinitrate group (1993 patients assessed; >99%) and the no 
glyceryl trinitrate group (2002 patients assessed; >99%) 
did not diﬀ er (common OR for a worse outcome with 
glyceryl trinitrate 1·01, 95% CI 0·91–1·13, p=0·83; 
ﬁ gure 2). A formal goodness-of-ﬁ t test gave no evidence 
that the proportional odds assumption was violated 
(p=0·11). Functional outcome (mRS) did not diﬀ er across 
the six treatment groups when we took account of the 
partial-factorial design (appendix p 18). When we assessed 
the primary outcome across prespeciﬁ ed subgroups, 
signiﬁ cant interactions were present with a shift in the 
distribution of mRS in patients randomised glyceryl 
trinitrate within 6 h of stroke onset (pinteraction=0·031), and in 
women given glyceryl trinitrate (pinteraction=0·044) compared 
with no treatment (ﬁ gure 3). Although the interaction 
term was not signiﬁ cant for carotid stenosis, there was no 
evidence of harm in patients with an occluded carotid 
artery, although the group size was small. There was no 
interaction between treatment and age, systolic blood 
pressure at baseline, type of stroke (ischaemic, 
haemorrhagic), or continuing versus stopping prestroke 
antihypertensive drugs (ﬁ gure 3).
The cumulative risk of all-cause death (mRS 6) during 
follow-up did not diﬀ er between the group given glyceryl 
trinitrate and the group not given glyceryl trinitrate 
(table 2, appendix p 24). Glyceryl trinitrate had no 
signiﬁ cant eﬀ ects on any of the secondary outcomes 
Figure 3: Subgroup analysis of eﬀ ects on functional outcome at 90 days for glyceryl trinitrate versus no 
glyceryl trinitrate
Two-sided p values are for the interaction between subgroup and allocated treatment. OCSP=Oxfordshire 
Community Stroke Project. GTN=glyceryl trinitrate.
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measured at day 90, including activities of daily 
living (Barthel index), cognition (modiﬁ ed telephone 
mini-mental state examination, telephone interview 
for cognition scale, verbal ﬂ uency), quality of life 
(EQ-5D-HUS, EuroQoL-visual analogue scale), or mood 
(Zung depression scale; table 2). Patients given glyceryl 
trinitrate were more likely to have headache or clinical 
hypotension during treatment than were those not given 
glyceryl trinitrate. The overall rate of serious adverse 
events occurring by day 7 (end of treatment) or day 90 did 
not diﬀ er between the two groups (appendix p 19).
There was no diﬀ erence in the distribution (shift) in the 
mRS at day 90 between patients who continued their blood 
pressure-lowering drugs (1050 patients; 99·7%) or stopped 
taking their drugs (1040 patients; >99%; common OR for a 
worse outcome in continue group 1·05, 95% CI 0·90–1·22, 
p=0·55; ﬁ gure 2). A formal goodness of ﬁ t test gave no 
evidence that the proportional odds assumption was 
violated (p=0·84). The eﬀ ects of the treatments were consis-
tent across all prespeciﬁ ed subgroups (data not shown).
The rates of death from any cause were similar for 
continue and stop groups (table 2, appendix p 24). 
However, patients who continued their blood 
pressure-lowering drugs were signiﬁ cantly more likely to 
have died in hospital or been discharged to an institution, 
and be dead or disabled (Barthel index <60) by day 90 
than were those who stopped treatment (table 2). The 
continue group had signiﬁ cantly lower cognition scores, 
whether assessed using the modiﬁ ed telephone 
mini-mental state examination or telephone interview for 
cognition scale, than had the stop group. The rate 
of severe hypertension, as determined by the local 
investigator, was signiﬁ cantly lower in the continue group 
than in the stop group (table 2). Although the total 
number of serious adverse events did not diﬀ er between 
the groups, pneumonia was more common in patients 
who continued taking their drugs (appendix p 19). Most 
cases of pneumonia occurred in patients who had 
dysphagia (97 of 151 patients; 64%) and many occurred 
when blood pressure tablets were taken despite the 
Glyceryl trinitrate vs no glyceryl trinitrate analysis Continue vs stop analysis
N Glyceryl 
trinitrate 
(n=2000)
No glyceryl 
trinitrate 
(n=2011)
OR or MD (95% CI) Two-sided 
p value
N Continue 
(n=1053)
Stop (n=1044) OR or MD (95% CI) Two-sided 
p value
Day 7 (or discharge)
Death, all cause 4001 61 (3%) 58 (3%) 1·12 (0·76–1·64) 0·57 2095 34 (3%) 27 (3%) 1·18 (0·69–2·00) 0·55
SSS score (out of 58) 3991 39·1 (16) 38·5 (16) 0·62 (–0·38 to 1·61)* 0·46 2088 37·1 (17) 38·4 (16) –1·25 (–2·65 to 0·16)* 0·28
Neurological deterioration† 3991 177 (9%) 194 (10%) 0·88 (0·71–1·10) 0·28 2088 107 (10%) 105 (10%) 1·00 (0·74–1·34) 0·99
Recurrent stroke‡ 3997 42 (2%) 31 (2%) 1·37 (0·85–2·20) 0·19 2093 30 (3%) 18 (2%) 1·64 (0·90–3·00) 0·10
Symptomatic intracranial 
haemorrhage‡
4000 22 (1%) 18 (1%) 1·20 (0·63–2·29) 0·59 2095 12 (1%) 11 (1%) 1·03 (0·43–2·44) 0·95
Headache‡ 4000 360 (18%) 170 (9%) 2·39 (1·96–2·92) <0·0001 2095 123 (12%) 117 (11%) 1·11 (0·84–1·47) 0·46
Hypotension‡ 4000 53 (3%) 15 (1%) 3·55 (1·99–6·35) <0·0001 2095 24 (2%) 16 (2%) 1·58 (0·82–3·02) 0·17
Hypertension‡ 4000 138 (7%) 155 (8%) 0·87 (0·68–1·11) 0·26 2095 60 (6%) 94 (9%) 0·65 (0·46–0·92) 0·015
Serious adverse event 4011 271 (14%) 261 (13%) 1·05 (0·88–1·26) 0·59 2097 147 (14%) 155 (15%) 0·93 (0·73–1·19) 0·56
Discharge data
Median hospital stay (days) 3985 11 (7–25) 11 (7–25) -0·34 (–1·81 to 1·12)* 1·00 2086 12 (7–28) 11 (7–26) 1·20 (–0·88 to 3·28)* 0·32
Death or institution 3986 716 (36%) 761 (38%) 1·08 (0·94–1·25) 0·29 2086 450 (43%) 389 (37%) 0·76 (0·62–0·93) 0·008
Day 90
Death 3996 233 (12%) 263 (13%) 0·89 (0·72–1·10) 0·27 2091 167 (16%) 146 (14%) 1·09 (0·83–1·42) 0·54
Death or institution 3980 554 (28%) 604 (30%) 0·88 (0·75–1·03) 0·11 2083 365 (35%) 323 (31%) 0·85 (0·69–1·06) 0·15
Barthel index (out of 100) 3970 66 (38) 63 (39) 2·18 (–0·23 to 4·59)* 0·11 2076 58 (41) 62 (39) –3·83 (–7·29 to 0·38)* 0·098
Barthel index <60 3970 654 (33%) 699 (35%) 0·90 (0·76–1·06) 0·19 2076 425 (41%) 365 (35%) 1·28 (1·02–1·59) 0·031
t-MMSE score 2506 11 (7) 11 (7) 0·33 (–0·22 to 0·88)* 0·13 1272 9 (7) 10 (7) –0·91 (–1·70 to 0·12)* 0·013
TICS-M score 2322 22·43 (14·93) 22·1 (15·49) 0·33 (–0·91 to 1·57)* 0·85 1179 19·01 (15·23) 21·11 (15·08) –2·11 (–3·84 to 0·37)* 0·044
Verbal ﬂ uency score 2366 9·31 (7·73) 9·21 (7·93) 0·1 (–0·53 to 0·73)* 0·82 1201 7·82 (7·48) 8·66 (7·54) –0·84 (–1·7 to 0·01)* 0·15
Health utility status 3952 0·49 (0·32) 0·48 (0·33) 0·01 (–0·01 to 0·03)* 0·87 2063 0·44 (0·33) 0·47 (0·33) –0·03 (–0·06 to 0·00)* 0·24
EQ-VAS 3440 56·5 (30.8) 55·7 (31·6) 0·79 (–1·29 to 2·88)* 0·70 1759 51·8 (32·4) 54·2 (31·6) –2·42 (–5·41 to 0·57)* 0·15
ZDS 3253 58·3 (23.7) 58·8 (24·6) –0·50 (–2·15 to 1·16)* 0·82 1659 62·0 (24·9) 61·1 (24·6) 0·94 (–1·44 to 3·32)* 0·43
Serious adverse event 4011 510 (26%) 499 (25%) 1·04 (0·90–1·20) 0·62 2097 308 (29%) 286 (27%) 1·10 (0·91–1·33) 0·35
Data are number of patients (%) or mean (SD). OR=odds ratio. MD=mean diﬀ erence. SSS=Scandinavian stroke scale. mRS: modiﬁ ed Rankin scale. t-MMSE=modiﬁ ed telephone mini-mental state examination. 
TICS-M=modiﬁ ed telephone interview for cognitive status. EQ=EuroQol. VAS=visual analogue scale. ZDS=Zung depression scale. *Values are MD. †Neurological deterioration was a decrease in SSS by more than 
5 points and decrease in consciousness on SSS by more than 2 points. ‡Clinical events determined by the investigator. 
Table 2: Secondary outcomes at days 7 and 90
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patient not having oral or enteral access (46 of 97 patients; 
47%). The rate of myocardial infarction did not diﬀ er for 
patients who continued versus stopped, either overall or 
for patients taking a β blocker before their stroke (seven vs 
nine, p=0·63). There were no signiﬁ cant diﬀ erences 
between the groups in any of the other prespeciﬁ ed 
secondary outcomes.
Discussion
ENOS assessed two aspects of blood pressure management 
in patients with acute stroke and hypertension. There was 
no eﬀ ect on functional outcome with either glyceryl 
trinitrate (compared with no glyceryl trinitrate) or of 
continuing prestroke antihypertensive drugs compared 
with stopping them temporarily when started within 48 h 
of stroke onset. The neutral results for glyceryl trinitrate 
were present across many functional outcome measures 
at day 90 including dependency, activities of daily living, 
cognition, mood, and quality of life, and might have 
several explanations. First, if lowering of blood pressure is 
important for outcome, the diﬀ erence in blood pressure 
between the group given glyceryl trinitrate and the group 
not given glyceryl trinitrate (7·0/3·5 mm Hg) might have 
been insuﬃ  cient. This diﬀ erence is twice that reported in 
the SCAST trial5 (3·3/1·3 mm Hg at day 2) in which oral 
candesartan was associated with a near-negative eﬀ ect on 
functional outcome, and about half of that observed in 
INTERACT-28 (systolic diﬀ erence 15 mm Hg) in which 
intensive lowering in patients with haemorrhagic stroke 
was associated with a near-positive eﬀ ect on outcome 
(panel). Second, lowering of blood pressure might be 
eﬃ  cacious only in patients with haemorrhagic stroke, as 
suggested by INTERACT-2.8 However, candesartan was 
associated with a worse outcome in the subgroup of 
patients with haemorrhage in SCAST.44 Nevertheless, 
trials in patients with ischaemic stroke (eg, CATIS7), or in 
which most patients had ischaemic stroke (BEST,23 
INWEST,24 IMAGES,6 SCAST5), were all neutral or 
negative. Third, treatment might have been started too 
late with an average time to randomisation of 26 h. Finally, 
tolerance to glyceryl trinitrate could have developed over 
the ﬁ rst few days, manifesting as a reduction in the eﬀ ect 
of the drug on blood pressure and seen in pilot trials,13,14 
and so the length of eﬀ ective treatment might have been 
insuﬃ  cient.
Functional outcome was improved in the patients given 
glyceryl trinitrate within 6 h and in women compared 
with men. The observation that treatment might be 
eﬀ ective if started very early is compatible with a previous 
small pilot trial in which glyceryl trinitrate improved 
functional outcome when given by paramedics outside of 
the hospital, with an average time to treatment of 55 min.16 
As in ENOS, glyceryl trinitrate did not change outcome in 
three hospital-based pilot trials14,15,45 when glyceryl 
trinitrate was given in the acute and subacute phases of 
stroke. The better eﬀ ect seen in women might show sex 
diﬀ erences in the nitric oxide pathway, as shown 
experimentally.46 The absence of harm in patients with 
carotid occlusion, although contrasting with theoretical 
concerns that blood pressure lowering might be harmful 
in haemodynamically signiﬁ cant arterial disease, is 
consistent with a pilot trial showing improvement in 
peri-infarct cerebral blood ﬂ ow with glyceryl trinitrate.15 
Whether these interactions show chance or a real eﬀ ect is 
not clear. But the planned multicentre phase 3 Rapid 
Implementation of Glyceryl Trinitrate-2 (RIGHT-2) trial 
will build on these results and test the safety and eﬃ  cacy 
of glyceryl trinitrate when given by paramedics within 4 h 
of the stroke ictus.
Although the primary outcome was neutral for the 
comparison of continue versus stop antihypertensive 
drugs, patients assigned to continue their blood 
pressure-lowering drugs did worse than did those who 
stopped their drugs for several secondary measures 
of outcome—discharge destination, activities of daily 
living (measured by Barthel index), and cognition 
(modiﬁ ed telephone Mini-Mental State Examination 
and Telephone Interview for Cognition Scale). These 
observations occurred despite some crossover between 
groups—ie, some patients assigned to continue treatment 
did not take their ﬁ rst treatment, usually due to the 
presence of dysphagia, whereas other patients who were 
randomly assigned to stop treatment continued it. These 
secondary ﬁ ndings could simply be due to chance or the 
eﬀ ect of comorbidities, and therefore might be of no 
clinical relevance. However, 80% of patients continued on 
drugs that inhibit the renin-angiotensin-aldosterone 
system—ie, an angiotensin-converting enzyme inhibitor, 
angiotensin-receptor antagonist, or β blocker, or a 
combination of these drugs. Other trials of renin-
angiotensin-aldosterone inhibitors during the acute 
phase of stroke have shown that these drugs were 
associated with a worse outcome, including BEST22 
(atenolol, propranolol) and SCAST23 (candesartan). 
Furthermore, a negative inotropic drug such as a β blocker 
might reduce cerebral perfusion further. However, in a 
post-hoc analysis of ENOS, we showed no interaction 
between the primary outcome and whether a renin-
angiotensin-aldosterone inhibitor was taken or not before 
the stroke (data not shown).
Most justiﬁ cations for continuing or stopping 
treatment, as listed in the introduction, are not 
supported by the results. Blood pressure did not fall 
rapidly or by a large amount (as occurred in the INWEST 
trial24) in the group assigned to continue treatment, 
except in a few patients who were being prescribed 
more than three drugs before their stroke. There was no 
evidence that the presence of carotid artery stenosis 
worsened outcome when blood pressure drugs were 
continued. And any post-randomisation hypertension 
in the group who stopped their drugs caused no 
apparent clinical problems. However, pneumonia was 
more common in patients who continued blood 
pressure-lowering treatment; although this ﬁ nding 
For more on the RIGHT-2 trial 
see http://www.right2-trial.org
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could be due to chance, it might also imply aspiration of 
those tablets that were continued in the presence of 
dysphagia. Pneumonia can worsen long-term outcome 
and therefore might explain poor results in activities of 
daily living, and death or discharge to an institution.
ENOS has several strengths, including the large 
sample size, generalisability due to wide inclusion 
criteria and recruitment of patients from several race 
and ethnic origin groups across ﬁ ve continents, central 
concealment of treatment assignment, collection 
prospectively of several functional outcomes and safety 
measures such as hypotension and hypertension; central 
assessment of outcomes at day 90 blinded to treatment 
assignment, very high rates of follow-up (>99 % of 
patients had their primary outcome recorded), and 
quality care at stroke units. In addition, the trial was a 
pragmatic test of real-world approaches to blood 
pressure management that included individuals over a 
wide time window representative of routine clinical 
practice, including patients with ischaemic stroke or 
haemorrhage, severe or mild stroke, and cortical or 
lacunar stroke. Glyceryl trinitrate was sourced locally 
from several manufacturers, further increasing the 
external validity of the overall trial. The 48 h time window 
for inclusion is a strength for the comparison of continue 
and stop groups since it covers the time during which 
most patients present with stroke.
However, several limitations are also present. First, 
glyceryl trinitrate was given in a single-blind design 
because no manufacturer was able to supply placebo 
patches. Patient-blinding was obtained with placement 
of a gauze dressing over a suitable area of skin out of 
view of the patient (eg, back or shoulders) with or 
without a glyceryl trinitrate patch underneath, an 
approach we have used before.15,16,47 Although headache 
occurred in both groups of patients, the rate was double 
for individuals randomised to glyceryl trinitrate and 
might have unmasked some patients. Similarly, the 
continue and stop groups of ENOS had to have an 
unmasked open-label design because it was not possible 
to prepare appropriate placebos when investigators did 
not know what antihypertensive drugs patients would 
be taking when enrolled. Nevertheless, outcomes 
measured at day 90 were assessed centrally by trained 
staﬀ  who were masked to treatment assignment and 
who were not involved in hospital care of enrolled 
patients. Second, some patients assigned to glyceryl 
trinitrate did not receive it for the recommended 
minimum treatment period of 4 days—reasons 
included earlier discharge from hospital or death, an 
adverse event such as headache, or withdrawal of 
consent. Adherence with treatment allocation was also 
not optimum for continue versus stop, particularly 
among patients allocated to stop antihypertensives. 
However, the resulting crossover would have been to 
dilute the diﬀ erence in outcomes between the groups, 
not to increase it or change the direction of the eﬀ ect. 
Third, the ﬁ rst dose of transdermal glyceryl trinitrate 
lowered blood pressure by only 7·0/3·5 mm Hg, a 
smaller eﬀ ect than was seen in our pilot trials, in which 
reductions at 1–2 h after treatment were 18–23 mm Hg.15,16 
The explanation for this discrepancy is not clear, but it 
is likely that the timing of blood pressure measurements 
relative to administration of glyceryl trinitrate was far 
more variable in this large pragmatic international trial 
than in the earlier explanatory single-centre studies. 
Supportive of this assertion, treatment with glyceryl 
trinitrate was associated with clinical hypotension in 
some patients. Fourth, some patients will have been 
taking blood pressure-lowering drugs for reasons other 
than the management of hypertension—although 
individual reasons were not collected in ENOS, 
α-receptor antagonists are used in men with benign 
prostatic hypertrophy, β blockers are used for heart rate 
management in patients with atrial ﬁ brillation, and 
angiotensin-modifying drugs and diuretics are used for 
the control of heart failure. 103 (5%) patients randomly 
assigned to continue versus stop did not have a history 
of high blood pressure before their stroke. And ﬁ nally, 
the trial started in 2001 at a time when modern medical 
interventions (stroke units, thrombolytics, statins) were 
not commonly available. However, 3182 (79%) patients 
were recruited from 2008 so most will have beneﬁ tted 
from modern guideline-based care.
Panel: Research in context
Systematic review
We did a meta-analysis of all randomised controlled trials 
based on an earlier version published for the SCAST trial.5 
We searched for reports in the Cochrane Library, PubMed, 
and Embase (up to Dec 11, 2013), and in relevant reference 
lists for trials of acute stroke in which blood pressure was 
lowered and for which information about functional 
outcome was available. For the full list of our search terms 
see Geeganage and Bath.43 Recent large trials were included: 
INTERACT-2, CATIS, and FAST-Mag.7,8 Data were available for 
19 787 patients in 16 trials. Heterogeneity was tested across 
four strata: only ischaemic stroke, mixed ischaemic and 
haemorrhagic stroke, only haemorrhagic stroke, and ENOS. 
Overall there was no eﬀ ect of lowering blood pressure on 
functional outcome, odds ratios 1·00 (95% CI 0·93–1·97; 
p=0·99). There was no statistical evidence of heterogeneity 
(χ² 18·6, p=0·23; I²=19%; appendix p28).
Interpretation
There is no evidence that lowering blood pressure improved 
functional outcome in patients with acute stroke. Although 
the meta-analysis does not show evidence of heterogeneity, 
evidence from hyperacute trials of haemorrhagic stroke and 
from a pilot trial of ultra-acute glyceryl trinitrate suggest 
that very early lowering of blood pressure might be 
eﬀ ective; future trials should focus on treatment within a 
few hours of stroke onset.
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Most patients with acute stroke have high blood 
pressure, an independent risk factor for a poor outcome. 
Although this and other trials of vasodepressant 
interventions were neutral,6,7 their results suggest that 
lowering blood pressure is, at least, free of serious 
hazard. Antihypertensive drugs will reduce blood 
pressure more quickly than will the spontaneous 
reduction that occurs over the ﬁ rst few days after stroke 
and will allow secondary prevention. Transdermal 
administration of a drug in acute stroke is advantageous 
since oral treatment is confounded by the presence of 
severe dysphagia in up to 50% of patients, whereas 
intravenous therapy needs intensive monitoring; 
additionally, transdermal treatment can be stopped and 
re-started according to clinical need.
In conclusion, we noted no beneﬁ t for lowering of 
blood pressure with glyceryl trinitrate in patients with 
acute stroke and raised blood pressure. The results are 
compatible with a neutral meta-analysis of previous 
trials of several strategies to lower blood pressure in 
patients with acute ischaemic, haemorrhagic, or mixed 
stroke.5 Although lowering of blood pressure might not 
be beneﬁ cial when started at an average of 26 h after 
stroke onset, glyceryl trinitrate has acceptable safety, 
including in patients with carotid stenosis, and potential 
beneﬁ ts when started within 6 h of stroke onset. There 
was no diﬀ erence in functional outcome measured 
using the mRS when we compared groups who 
continued versus stopped prestroke antihypertensive 
drugs. However, some secondary outcomes were worse 
in the group who continued treatment, although 
whether this ﬁ nding is due to chance or is a real eﬀ ect is 
not clear. Overall, ENOS provides no evidence for the 
strategy of immediately continuing prestroke blood 
pressure-lowering drugs after admission to hospital; 
indeed, such a policy might have a deleterious eﬀ ect. 
The main implication for practice is that it seems 
reasonable to withhold blood pressure-lowering drugs 
until patients with an acute stroke are medically and 
neurologically stable, and have suitable oral or enteral 
access to allow safe drug reintroduction. Nevertheless, 
post-acute blood pressure control is important to reduce 
the risk of subsequent vascular events and drugs will 
need to be restarted.
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